Anne Worsaae

Anne Worsaae has a diverse work experience spanning over three decades. Anne started their career in 1984 at Statens Serum Institut, where they worked as a Research Scientist. Their responsibilities included identifying Mycobacterial antigens important for T-cell reactivity in patients with Tuberculosis. Anne also worked as a Clinical Supervisor, responsible for analyzing incoming samples from hospitals.

In 1988, Anne joined the University of Copenhagen as a Research Scientist. Here, they focused on generating plasmids containing the MCH class II DQ beta 3,2 antigen for transfecting mammalian cells. Anne also worked on creating antigen presenting cells expressing different human MHC class II molecules to search for diabetes-specific antigens.

In 1989, Anne moved to Novo Nordisk as a Senior Research Scientist. Anne played a significant role in building a lab group funded by Eureka as part of an international project group studying intervention and prevention strategies in Diabetes type 1. Anne was one of the pioneers in implementing High Throughput Screening procedures for various cellular assays at Novo Nordisk. Additionally, they established and optimized a complement fixation assay used in antibody projects for safety package approval and M1 delivery.

Later, Anne worked as a Safety Surveillance Scientist at Novo Nordisk from 2015 to 2016.

Finally, in 2016, Anne joined Symphogen as a Principal Scientist. Further details about their role in this position are not provided.

Anne Worsaae received a Master of Science (MSc) degree in Biology, with a specialization in Immunology, from the University of Copenhagen in 1984. The exact duration of their education prior to 1984 is not provided.